Highly safe smallpox vaccine virus and vaccinia virus vector

Details Highly safe smallpox vaccine virus and vaccinia virus vector Highly safe smallpox vaccine virus and vaccinia virus vector

2003-12-05

2009-12-29

Mosher, Mary E (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Recombinant virus encoding one or more heterologous proteins...

C424S232100, C435S235100, C435S320100

Reexamination Certificate

active

07638132

ABSTRACT:
Objects of the present invention are to generate vaccine strains that undergo reversion (atavism) with difficulty and to provide smallpox vaccines with higher safety. The vaccine viruses are deficient in a part or the whole of the B5R gene of a vaccinia viral strain, LC16m8 or LC16mO, and produce no B5R gene products having normal functions. The vaccine viruses can be used as smallpox vaccines or vectors capable of expressing foreign genes. Hence, smallpox vaccines and vaccinia virus vectors are provided that produce no B5R gene products having normal functions due to reverse mutation.

REFERENCES:
patent: WO-90/12101 (1990-10-01), None
patent: WO 2004/087047 (2004-10-01), None
Mathew et al, Journal of General Virology 82:1199-1213 (2001) (cited in IDS filed Sep. 6, 2006).
Engelstad et al (Virology 194:627-637, 1993) (cited in IDS).
Takahashi-Nishimaki et al (Virology 181:158-164, 1991).
Sugimoto et al (Vaccine 12:675-681, 1994).
Smith et al (Journal of General Virology 83:2915-2931, 2002).
Cohen (Science 298:2314, 2002).
Katz et al (AIDS Research and Human retroviruses 13:1497-1500, 1997) (cited in IDS).
Kidokoro et al (Microbes and Infection 4:1035-1044, 2002).
Jin et al (Archives of Virology 138:315-330, 1994).
Masanobu Sugimoto et al., Kokusan Ten'nento Vaccine no Aratana Yakuwari, Protein, Nucleic acid and Enzyme, Sep. 2003, pp. 1693-1701, vol. 48, No. 12.
E Mathew et al., The extracellular domain of vaccinia virus protein B5R affects plaque phenotype, extracellular enveloped virus release and intracellular actin tail formation, J.Virol., 1998, pp. 2429-2438, vol. 72, No. 3.
E Herrera et al., Functional analysis of vacinia virus B5R protein: essential role in virus envelopment is independent of a large protein of the extracellular domain., J. Virol, 1998, pp. 294-302, vol. 72, No. 1.
EJ Wolffe et al., Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination, J.Virol, 1993, pp. 4732-4741, vol. 67, No. 8.
EC Mathew et al., A mutational analysis of the vaccinia virus B5R protein, J.Gen.Virol, 2001, pp. 1199-1213, vol. 82, Pt. 5.
MM Lorenzo et al., Functional analysis of vaccinia virus B5R protein: role of the cytoplasmic tail, Virology, 1998, pp. 450-457, vol. 252, No. 2.
Engelstad, M. et al.; Virology, vol. 194, No. 2, pp. 627-637 (1993), XP 002443993.
Katz, E. et al.; Aids Research and Human Retroviruses; vol. 13, No. 17, pp. 1497-1500 (1997); XP009038314.
Boursnell, M.E.G. et al.; Vaccine, vol. 14, No. 16, pp. 1485-1494 (1996); XP 004063302.
So Hashizume, Clinical Virology, vol. 3, pp. 53-62, No. 3, (1975).

Affiliated with

Also associated with

Rating

Highly safe smallpox vaccine virus and vaccinia virus vector does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Highly safe smallpox vaccine virus and vaccinia virus vector, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Highly safe smallpox vaccine virus and vaccinia virus vector will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4149512